{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:51:35Z","timestamp":1740178295812,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,27]]},"DOI":"10.1182\/bloodadvances.2023012128","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T16:42:32Z","timestamp":1709052152000},"page":"1051-1052","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Bridging therapy before axi-cel for lymphoma"],"prefix":"10.1182","volume":"8","author":[{"given":"Safia","family":"Belbachir","sequence":"first","affiliation":[{"name":"1Haematology Service, Fiona Stanley Hospital, Perth, WA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0408-8455","authenticated-orcid":false,"given":"Duncan","family":"Purtill","sequence":"additional","affiliation":[{"name":"1Haematology Service, Fiona Stanley Hospital, Perth, WA, Australia"},{"name":"2Haematology Department, PathWest Laboratory Medicine, Perth, WA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"4","key":"2024022716422710500_bib1","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1182\/bloodadvances.2023011489","article-title":"Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium","volume":"8","author":"Jain","year":"2024","journal-title":"Blood Adv"},{"issue":"26","key":"2024022716422710500_bib2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024022716422710500_bib3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood-2019-129624","article-title":"Characteristics and outcomes of patients receiving bridging therapy while awaiting manufacture of standard of care axicabtagene ciloleucel CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2024022716422710500_bib4","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jcyt.2022.03.009","article-title":"Systematic review and meta-analysis of the association between bridging therapy and outcomes of chimeric antigen receptor T cell therapy in patients with large B cell lymphoma","volume":"24","author":"Sun","year":"2022","journal-title":"Cytotherapy"},{"issue":"12","key":"2024022716422710500_bib5","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can\u00a0improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2024022716422710500_bib6","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 3","key":"2024022716422710500_bib7","doi-asserted-by":"crossref","first-page":"e7340170","DOI":"10.1097\/01.HS9.0000971712.73401.70","article-title":"Axicabtagene ciloleucel vein-to-vein time in trial or real-world settings vs other CAR T-cell therapies for relapsed\/refractory large B-cell lymphoma: a systematic literature review and meta-analysis","volume":"7","author":"Locke","year":"2023","journal-title":"Hemasphere"},{"issue":"4","key":"2024022716422710500_bib8","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024022716422710500_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2023","journal-title":"Haematologica"},{"issue":"3","key":"2024022716422710500_bib10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.18209","article-title":"A\u00a0national service for delivering CD19 CAR-T in large B-cell lymphoma\u2013the UK real-world experience","volume":"198","author":"Kuhnl","year":"2022","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/4\/1051\/2215924\/blooda_adv-2023-012128-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/4\/1051\/2215924\/blooda_adv-2023-012128-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T16:42:39Z","timestamp":1709052159000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/4\/1051\/515007\/Bridging-therapy-before-axi-cel-for-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,2,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012128","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2024,2,27]]}}}